Next 10 |
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Suppor...
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors PR Newswire Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 13, 2024 /PRNews...
2024-05-09 03:45:26 ET More on Genprex Seeking Alpha’s Quant Rating on Genprex Historical earnings data for Genprex Financial information for Genprex Read the full article on Seeking Alpha For further details see: Genprex co-founder, CEO pa...
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner PR Newswire Ryan Confer Appointed Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" o...
Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, will be participating at two conferences during May. According to the announcement, Genprex CFO Ryan Confer will be presenting at the Sidoti Microcap...
Genprex to Present and Participate at Upcoming May Investor and Industry Conferences PR Newswire AUSTIN, Texas , May. 1, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developin...
Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting PR Newswire Compelling Data Validates the Potential...
2024-04-03 08:46:01 ET More on Genprex Genprex to effect 1-for-40 reverse stock split to regain Nasdaq compliance Seeking Alpha’s Quant Rating on Genprex Historical earnings data for Genprex Financial information for Genprex Read the full art...
Genprex Expands Clinical Trial Sites for Acclaim-3 Clinical Study of Reqorsa® Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Multiple clinical trial sites to be opened under collaboration with large network of community-based oncol...
Genprex (NASDAQ: GNPX) is a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes. The company today announced that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizin...
News, Short Squeeze, Breakout and More Instantly...
Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire Expects to Initiate the Phase 2 Expansion Study in the Second Half of 2024 Acclaim-3 Study Suppor...
Genprex Announces the Appointment of Jose A. Moreno Toscano as Chairman of the Board of Directors PR Newswire Follows the Recent Appointment of Ryan Confer as Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 13, 2024 /PRNews...
Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner PR Newswire Ryan Confer Appointed Genprex President and CEO and to its Board of Directors AUSTIN, Texas , May 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" o...